Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

@article{Ban2008CardioprotectiveAV,
  title={Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways},
  author={Kiwon Ban and Mohammad Hossein Noyan-Ashraf and Judith Hoefer and Steffen Sebastian Bolz and Daniel J. Drucker and Mansoor Husain},
  journal={Circulation},
  year={2008},
  volume={117},
  pages={2340-2350}
}
Background— The glucagon-like peptide 1 receptor (GLP-1R) is believed to mediate glucoregulatory and cardiovascular effects of the incretin hormone GLP-1(7-36) (GLP-1), which is rapidly degraded by dipeptidyl peptidase-4 (DPP-4) to GLP-1(9-36), a truncated metabolite generally thought to be inactive. Novel drugs for the treatment of diabetes include analogues of GLP-1 and inhibitors of DPP-4; however, the cardiovascular effects of distinct GLP-1 peptides have received limited attention. Methods… Expand
Cardiovascular biology of the incretin system.
TLDR
The cardiovascular biology of GLP-1R agonists and DPP-4 inhibitors is reviewed, including direct and indirect effects on cardiomyocytes, blood vessels, adipocytes, the control of blood pressure, and postprandial lipoprotein secretion. Expand
Impact of glucagon-like peptide-1 on myocardial glucose metabolism revisited
TLDR
The dogma that GLP-1 receptor stimulation may provide beneficial cardiovascular effects, possibly due to enhanced myocardial energetic efficiency, by increasing myocardian glucose uptake is focused on. Expand
Non-insulin injectable treatments (glucagon-like peptide-1 and its analogs) and cardiovascular disease.
TLDR
Preliminary data in animals with available GLP-1 receptor agonists and cardiac disease suggest that exenatide has beneficial effects in porcine models of ischemic heart disease and clinical trials with liraglutide show significant improvements in weight, systolic blood pressure, lipid profiles, and other cardiovascular risk factors. Expand
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
TLDR
The cardiovascular actions of GLP-1R agonists and DPP-4 inhibitors are reviewed, with a focus on the translation of mechanisms derived from preclinical studies to complementary findings in clinical studies. Expand
The effect of glucagon-like peptide 1 on cardiovascular risk
TLDR
This Review highlights the mechanisms targeted by GLP-1-based therapies, and emphasizes current developments in incretin research that are relevant to cardiovascular risk and disease, as well as treatment with GLp-1 receptor agonists. Expand
Glucagon-like peptide-1 (GLP-1) and protective effects in cardiovascular disease: a new therapeutic approach for myocardial protection
  • T. Zhao
  • Medicine
  • Cardiovascular Diabetology
  • 2013
TLDR
Current evidence supporting the use of GLP-1 in experimental animal models and human trials with the ischemic and non-ischemic heart is reviewed and their molecular mechanisms and potential as a new therapeutic approach are discussed. Expand
Glucagon-like peptide-1 receptor action in the vasculature
TLDR
The described actions of GLP-1/GLp-1R agonists on the vascular endothelium, which include antiproliferative actions on VSMCs and endothelial cells, reductions in oxidative stress, and increases in nitric oxide generation, are reviewed. Expand
Cardiovascular actions of incretin-based therapies.
TLDR
Recent experimental and clinical advances that reveal how GLP-1R agonists and DPP-4 inhibitors affect the normal and diabetic heart and coronary vasculature, often independent of changes in blood glucose are reviewed. Expand
Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation
TLDR
Glucagon-like peptide 1, its degradation product GLP-1(9–36) and Liraglutide exert similar inhibitory effects on platelet activation, suggesting a potential protective effect on the cardiovascular system. Expand
Glucagon-Like Peptide-1
TLDR
There is a need for high-quality, well-designed research to evaluate GLP-1 as a cardioprotective agent for use in real-world practice, and the evidence for each of these mechanisms is assessed. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 50 REFERENCES
Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat
TLDR
GLP-1 and amylin represent two additional peptides which may modulate pulmonary vascular tone and are compared with the well-known actions of calcitonin gene-related peptide and vasoactive intestinal peptide. Expand
Cardiac function in mice lacking the glucagon-like peptide-1 receptor.
TLDR
New evidence is provided implicating an essential role for GLP-1R in the control of murine cardiac structure and function in vivo, as well as highlighting the importance of echocardiography and histology in the determination of this role. Expand
Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury.
TLDR
It is shown for the first time that GLP-1 protects against myocardial infarction in the isolated and intact rat heart, and this finding may represent a new therapeutic potential for this class of drug currently undergoing clinical trials in the treatment of type 2 diabetes. Expand
Direct Effects of Glucagon-Like Peptide-1 on Myocardial Contractility and Glucose Uptake in Normal and Postischemic Isolated Rat Hearts
TLDR
GLP-1 has direct effects on the normal heart, reducing contractility, but increasing myocardial glucose uptake through a non-Akt-1-dependent mechanism, distinct from the actions of insulin. Expand
Biologic actions and therapeutic potential of the proglucagon-derived peptides
  • D. Drucker
  • Medicine
  • Nature Clinical Practice Endocrinology &Metabolism
  • 2005
TLDR
The modulation of proglucagon-derived peptides has therapeutic potential for the treatment of diabetes and intestinal disease. Expand
Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy.
TLDR
In DCM, GLP-1-(9-36) mimics the effects ofGLP- 1-36 in stimulating myocardial glucose uptake and improving left ventricular (LV) and systemic hemodynamics through insulinomimetic as opposed to insulinotropic effects. Expand
Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons.
TLDR
It is reported here that centrally and peripherally administered GLP-1R agonists dose-dependently increased blood pressure and heart rate and this suggests that the central GLp-1 system represents a regulator of sympathetic outflow leading to downstream activation of cardiovascular responses in vivo. Expand
Glucagon-Like Peptide-1 Increases cAMP but Fails to Augment Contraction in Adult Rat Cardiac Myocytes
TLDR
GLP-1 increases cAMP but fails to augment contraction, suggesting the existence of functionally distinct adenylyl cyclase/cAMP/protein kinase A compartments, possibly determined by unique receptor signaling microdomains that are not controlled by pertussis toxin–sensitive G proteins or by enhanced local PDE or phosphatase activation. Expand
The biology of incretin hormones.
TLDR
Current concepts of incretin action are summarized and the potential therapeutic utility of GLP-1 receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes is highlighted. Expand
Glucagon Like Peptide-1 is Protective Against Myocardial Ischemia/Reperfusion Injury when Given Either as a Preconditioning Mimetic or at Reperfusion in an Isolated Rat Heart Model
TLDR
It is hypothesised that since GLP-1 has the ability to activate these kinases, it may protect against infarction when given either before ischemia (as a preconditioning mimetic) or at reperfusion. Expand
...
1
2
3
4
5
...